Protalix BioTherapeutics (PLX)

P/S ratio as of January 2026 (TTM): 2.69

According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.14. At the end of 2025 the company had a P/S ratio of 2.66.

P/S ratio history for Protalix BioTherapeutics from 2001 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	2.66	5.25%
2024	2.52	27.27%
2023	1.98	36.07%
2022	1.46	47.48%
2021	0.9880	-48.65%
2020	1.92	116.21%
2019	0.8899	-1.84%
2018	0.9065	-81.12%
2017	4.80	-19.81%
2016	5.99
2015	N/A	-100%
2014	11.4	-64.03%
2013	31.6	124.11%
2012	14.1	-66.53%
2011	42.1	-66.86%
2010	127	-90.79%
2009	> 1000	-100%
2008	> 1000
2001	> 1000

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Amicus Therapeutics FOLD	7.40	175.58%	🇺🇸 USA
Neurocrine Biosciences NBIX	4.96	84.77%	🇺🇸 USA
Pfizer PFE	2.32	-13.69%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	2.17	-19.13%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Protalix BioTherapeutics (PLX)

P/S ratio as of January 2026 (TTM): 2.69